Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets
Article first published online: 2 APR 2001
Copyright © 2001 Wiley-Liss, Inc.
Annals of Neurology
Volume 50, Issue 1, pages 6–16, July 2001
How to Cite
Guo, X., Dillman, J. F., Dawson, V. L. and Dawson, T. M. (2001), Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets. Ann Neurol., 50: 6–16. doi: 10.1002/ana.1030
- Issue published online: 26 JUN 2001
- Article first published online: 2 APR 2001
- Manuscript Accepted: 27 JAN 2001
- Manuscript Revised: 22 JAN 2001
- Manuscript Received: 17 NOV 2000
- USPHS. Grant Number: NS38377
- Edward D. and Anna Mitchell Family Foundation
Cyclosporin A (CsA) and FK506 (tacrolimus) are immunosuppresants that are widely used in organ transplantation. CsA is an 11-member cyclic peptide, whereas FK506 is a macrolide antibiotic. Recently, these powerful and useful compounds have become of great interest to neuroscientists for their unique neuroprotective and neuroregenerative effects. These drugs and nonimmunosuppressive analogs protect neurons from the effects of glutamate excitotoxicity, focal ischemia, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic cell death. They also stimulate functional recovery of neurons in a variety of neurologic injury paradigms. These drugs exert their effects via immunophilins, the protein receptors for these agents. The immunophilin ligands show particular promise as a novel class of neuroprotective and neuroregenerative agents that have the potential to treat a variety of neurologic disorders.